sample thesis title with a concise and accurate description

Preface
Chapter 2 is based on work done at UBC, the BC Cancer Agency, and Aquinox
Pharmaceuticals Inc. The author is responsible for the synthesis and characterization of all
2.18 analogues. In addition to the author, Dr. Matt Nodwell and Dr. Chelsea Wang
constructed 2.20/2.34/2.42/2.43 for biological testing. Single crystal X-ray diffraction
analysis was carried out by Dr. Brian O. Patrick. STDD NOE NMR experiments were run by
Dr. David Williams. The SHIP1 phosphatase assay screening was done by Andrew Ming-
Lum under the guidance of Dr. Alice-F. Mui at the BC Cancer Agency. The solubility of 2.18
analogues, the AKT phosphorylation inhibition assay, some measurements of SHIP1
enzymatic assay, and the in vivo PCA model was completed by Aquinox Pharmaceuticals
Inc.
The work in chapter 3 has been published: Meimetis, Labros G.; Williams David E.;
Mawji, Nasrin R.; Banuelos, Adriana.; Lal, Aaron A.; Park, Jacob J.; de Voogdt, Nicole J.;
Fernandez J.C.; Sadar, Marianne D.; and Andersen, Raymond J. Niphatenones A and B,
glycerol ethers from the sponge Niphates Digitalis block androgen receptor transcriptional
activity in prostate cancer cells: structure elucidation, synthesis, and biological activity. J.
Med. Chem. (2012), 55(1), 503-514. Copyright 2012 American Chemical Society.
http://pubs.acs.org/doi/pdf/10.1021/jm2014056. The author was responsible for writing the
experimental section as it relates to all synthetic compounds. The author is responsible for
the construction and characterization of all synthetic compounds. Dr. David Williams is
responsible for the isolation and structure determination of niphatenones A (3.8) and B (3.9).
Nasrin R. Mawji, Adriana Banuelos, Aaron A. Lal, and Jacob J. Park under the leadership of
Dr. Marianne D. Sadar at the BC Cancer Agency were responsible for generating all of the
iv